Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|December 18, 2018
FDA Puts Chinese Manufacturer on Import Alert
Author(s)Pharmaceutical Technology Editors
The agency sent a warning letter to Cao Medical Equipment Co., Ltd. after inspectors found CGMP violations at the company’s Langfang, Hebei facility.
Advertisement
FDA sent a
Specifically, the warning letter states that manufacturing areas were exposed to “the outdoor environment where it is exposed to vermin, animal waste, and various contaminants … In addition, you do not protect your (b)(4) from the ingress and proliferation of objectionable microorganisms.”
According to FDA, the company did not test finished drug products for total aerobic microbial count and objectionable microorganisms prior to release and distribution. The company also failed to test batches for identity and strength of API before release. “Without this testing, you do not have scientific evidence that all drug product batches you manufactured meet their established specifications prior to release,” the agency stated in the letter. Purity, strength, and quality were also not tested in samples of each component, and reliability of component supplier’s test analyses were not properly validated.
Proper process control written procedures were not established, according to FDA. “You have not validated the processes used to manufacture your drug products, you did not define or identify critical process parameters, and you lack an ongoing program for monitoring process controls to ensure stable manufacturing operations and consistent drug quality,” the agency stated.
In the letter, FDA stated that the company’s response was inadequate, and the company continued to ship drugs to the United States after it said it would stop manufacturing and distributing drugs to the US. FDA placed the company on Import Alert 66-40 on November 26, 2018 and recommended the company acquire a CGMP consultant before resuming production.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement